Anaptys to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

 

• Designed to unlock potential value by creating two independent, publicly traded companies with different business objectives and opportunities
• Upon completion, the royalty management company will manage royalties and milestone payments from financial collaborations, including Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning their value
• Upon completion, the biopharma operations company will focus on development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases, including rosnilimab, ANB033 and ANB101
• Company to host a conference call with investors today at 4:30pm ET/1:30pm PT
• Anaptys will host an investor call and live webcast to discuss the announcement today, Monday, Sept. 29, 2025, at 4:30pm ET / 1:30pm PT. A live webcast will be available on the investor section of the Anaptys website at https://ir.anaptysbio.com/presentations-and-events. A replay of the webcast will be available for at least 30 days following the event.
• https://finviz.com/news/178763/anaptys-announces-intent-to-separate-biopharma-operations-from-substantial-royalty-assets-by-year-end-2026